US Patent

US11247981 — Metalloenzyme inhibitor compounds

Method of Use · Assigned to Mycovia Pharmaceuticals Inc · Expires 2033-05-09 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds with metalloenzyme modulating activity and methods for treating diseases or symptoms mediated by such metalloenzymes.

USPTO Abstract

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Drugs covered by this patent

Vivjoa (OTESECONAZOLE) · Mycovia Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3366`	—	Vivjoa

Patent Metadata

Patent number: US11247981
Jurisdiction: US
Classification: Method of Use
Expires: 2033-05-09
Drug substance claim: No
Drug product claim: No
Assignee: Mycovia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.